A REIT With Great V...
Health Care: Drugs
StemCells Inc. (STEM: NASDAQ)
$1.87 0.01 | 0.54%
05/22/13 - 04:00 PM ET
Company Profile
| Price and Volume | |
|---|---|
| Recent Price | 1.86 |
| 52 Week High | 2.67 |
| 52 Week Low | 0.59 |
| Avg. Daily Vol. (Mil) | 0.31 |
| Beta (3 year) | 2.05 |
| Share Related Items | |
| Mkt Cap (Mil) | 72.50 |
| Shares Out (Mil) | 38.98 |
| Float (Mil) | 38.25 |
| Dividend Information | |
| Yield % | 0.00 |
| Annual Dividend | 0.00 |
| Payout Ratio | 0.00 |
| Financial Strength | |
| Quick Ratio | 4.60 |
| Current Ratio | 5.00 |
| LT Debt/ Equity | 0.01 |
| Total Debt / Equity | 0.03 |
| Valuation Ratios | |
| Price Earnings | n.a. |
| Price/Sales | 71.92 |
| Price/Book | 7.10 |
| Price/Cash Flow | -2.20 |
| Per Share Data | |
| Earnings | -0.68 |
| Sales | 0.03 |
| Book Value | 0.26 |
| Cash Flow | -0.85 |
| Business Summary | |
|---|---|
| StemCells, Inc. is engaged in the research, development, and commercialization of stem cell therapeutics. | |
| General Information | |
| 7707 Gateway Boulevard
Newark, CA 94560 |
|
| www.stemcellsinc.com | |
| Industry : Drugs | |
| Sector: Health Care | |
| Employees: 49 | |
| CEO: Martin M. Mcglynn | |
| Short Interest | |
| Current Month (Mil) | 2.81 |
| Previous Month (Mil) | 2.93 |
| Short Interest Ratio (Days) | 10.50 |
| Management Effectiveness | |
| Return on Equity | n.a. |
| Return on Assets | -137.60 |
| Return on Investments | -331.00 |
| Profitability | |
| Gross Margin | 74.40 |
| EBIT Margin | n.a. |
| Profit Margin | 0.00 |
Portfolios with STEM
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Setting Up...
- User8 Stocks Under $10 Making B...
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- UserStocks
- Contributor5 Biggest Drug-Stock Losers...
Latest STEM Headlines from TheStreet
- StemCells, Inc. Reports First Quarter 2013 Financial Results And Provides Business Update 05.09.13 | 04:05 pm
- StemCells, Inc. Announces Webcast To Discuss First Quarter 2013 Financial Results And Business Update 05.07.13 | 09:05 am
- StemCells, Inc. Adds Byers Eye Institute At Stanford As Second Site For Phase I/II Clinical Trial In Dry Age-Related Macular Degeneration 04.18.13 | 09:04 am
- StemCells, Inc. To Participate At 2013 Regen Med Investor Day In New York 04.15.13 | 09:04 am
- StemCells, Inc. Enters Agreement To Receive $19.3 Million From California Institute For Regenerative Medicine To Help Fund IND For Alzheimer's Disease 04.11.13 | 09:04 am
- CORRECTION -- StemCells, Inc. Closes $10 Million Debt Financing 04.09.13 | 04:04 pm
- StemCells, Inc. Closes $10 Million Debt Financing 04.09.13 | 09:04 am
- StemCells, Inc. Expands Patent Portfolio 03.20.13 | 09:03 am
- StemCells, Inc. Reports Fourth Quarter And Full Year 2012 Financial Results And Provides Business Update 03.19.13 | 09:03 am
- 4 Biotech Stocks Under $5 to Watch 03.15.13 | 07:03 am
Press Releases for STEM
- Over $400 Million Raised By U.S. Life Sciences Companies Through At-the-Market (ATM) Offerings In 2012, Reports Brinson Patrick - PR Newswire 04.08.13 | 08:04 am
Partner Headlines for STEM
- Brainstorm's Breakthrough ALS Clinical Data Shows The Promise In Stem Cell Therapy - Seeking Alpha 03.28.13 | 09:03 am
- StemCells Partners With R Biomedical - Benzinga 10.30.12 | 09:10 am
- Neuralstem Swinging For The ALS Fences - Seeking Alpha 10.29.12 | 09:10 am
- 5 Bio-Pharmas On The Rise With Potential Groundbreaking And Lifesaving Treatments - Seeking Alpha 10.09.12 | 09:10 am
- StemCells Says Achieved First Neural Stem Cell Transplant Into Patient With Sensory Function Below the Level of Injury - Benzinga 09.27.12 | 09:09 am
- Why the bear market is finally ending - NASDAQ 09.13.12 | 01:09 pm
- Today's Market News To Trade On: 5 Stocks Moving On News - Seeking Alpha 08.31.12 | 08:08 am
- Nexen ENTERS Into Agreement With CNOOC and 4 Hot Stocks On the Move - Wall St. Cheat Sheet 07.23.12 | 04:07 am
- One Stock To Buy, Two Avoids, And A Swing Trade From Last Week's Big Biotech News Movers - Seeking Alpha 07.21.12 | 06:07 am
- Healthcare Stock Insights: Vivus Wins FDA Diet Drug THUMBS UP, StemCells Give BACK - Wall St. Cheat Sheet 07.19.12 | 08:07 am
